Search research articles
Contact Us
Filters
Showing results (21-30 of 48) with videos related to
Page
of 5
Sort By:
Applied Health Economics and Health Policy
|
November 15, 2023
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine
|
July 16, 2024
Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032]
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine
|
April 5, 2024
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
The American Journal of Tropical Medicine and Hygiene
|
August 15, 2012
Total economic cost and burden of dengue in Nicaragua: 1996-2010
Zachary S Wettstein, Michael Fleming, Aileen Y Chang, et al.
Public Health
|
October 29, 2025
Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society
|
June 1, 2024
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults
Angela R Wateska, Mary Patricia Nowalk, Shoroq M Altawalbeh, et al.
American Journal of Preventive Medicine
|
February 25, 2026
Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis
Angela R Wateska, Shoroq M Altawalbeh, Mary Patricia Nowalk, et al.
Vaccine
|
July 3, 2025
Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 10, 2024
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Influenza and Other Respiratory Viruses
|
September 22, 2011
The potential economic value of a 'universal' (multi-year) influenza vaccine
Bruce Y Lee, Julie H Y Tai, Sarah M McGlone, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 48) with videos related to
Sort By:
Page
of 5
Applied Health Economics and Health Policy
|
November 15, 2023
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine
|
July 16, 2024
Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032]
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine
|
April 5, 2024
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
The American Journal of Tropical Medicine and Hygiene
|
August 15, 2012
Total economic cost and burden of dengue in Nicaragua: 1996-2010
Zachary S Wettstein, Michael Fleming, Aileen Y Chang, et al.
Public Health
|
October 29, 2025
Public health effects of adult pneumococcal vaccination choice amid increased serotype 4 rates in US subpopulations
Kenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society
|
June 1, 2024
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults
Angela R Wateska, Mary Patricia Nowalk, Shoroq M Altawalbeh, et al.
American Journal of Preventive Medicine
|
February 25, 2026
Impact of Serotype Uncertainty on Adult Pneumococcal Vaccine Options: A Value of Information Analysis
Angela R Wateska, Shoroq M Altawalbeh, Mary Patricia Nowalk, et al.
Vaccine
|
July 3, 2025
Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 10, 2024
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis
Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, et al.
Influenza and Other Respiratory Viruses
|
September 22, 2011
The potential economic value of a 'universal' (multi-year) influenza vaccine
Bruce Y Lee, Julie H Y Tai, Sarah M McGlone, et al.
Page
of 5